Treatment Overview
Cancer risk stratification in Korea is a comprehensive evaluation to categorize patients based on their likelihood of developing or progressing with prostate cancer. It combines PSA testing, imaging, genetic assessment, and biopsy results to classify patients into low, intermediate, or high-risk categories. This approach allows for personalized monitoring and treatment strategies, improving early detection and outcomes.
Korean hospitals use advanced diagnostic tools and expert urologists to provide accurate risk assessment for both local and international patients.
Purpose & Benefits
The purpose of cancer risk stratification is to:
- Identify patients at higher risk for aggressive prostate cancer
- Guide personalized treatment or active surveillance plans
- Avoid overtreatment for low-risk patients while focusing on those who need intervention
Benefits include:
- Targeted early detection of clinically significant prostate cancer
- Personalized care plans based on risk category
- Integration with advanced diagnostics such as PHI, 4Kscore, and mpMRI
- Reduces unnecessary biopsies and interventions
- Supports timely intervention to improve long-term outcomes
Ideal Candidates
Cancer risk stratification is recommended for men who:
- Have elevated PSA levels or abnormal PSA trends
- Are diagnosed with low- or intermediate-risk prostate cancer and need monitoring
- Have family history or genetic predisposition
- Experienced previous negative biopsy but persistent clinical suspicion
- Require international-standard prostate cancer assessment
Korean urologists evaluate PSA levels, biopsy results, imaging, and genetic factors to determine risk categories accurately.
Possible Risks & Complications
The process is generally safe, but considerations include:
- Mild discomfort from blood draws
- Anxiety while awaiting results
- Rare false positives or negatives leading to further testing
- Minimal risks associated with imaging contrast agents
Techniques & Technology Used
Korean hospitals use advanced technologies for cancer risk stratification:
- PSA, Free PSA, PHI, and 4Kscore for biochemical risk assessment
- Multiparametric MRI (mpMRI) for lesion identification
- Fusion-guided biopsy for precise tissue sampling
- Genetic risk assessment for hereditary prostate cancer
- Risk classification algorithms (low, intermediate, high) integrated with clinical data
These technologies ensure an accurate and comprehensive risk evaluation.
Treatment Process in Korea
- Consultation & Initial Assessment – Review PSA, family history, and prior test results
- Blood Tests & Imaging – PSA, PHI, 4Kscore, and mpMRI performed as indicated
- Biopsy (if necessary) – Targeted or systematic biopsy guided by imaging
- Risk Stratification Analysis – Patients categorized into low, intermediate, or high risk
- Follow-Up & Personalized Recommendations – Active surveillance, treatment planning, or preventive strategies
Medical tourism coordinators assist international patients with scheduling, translation, and follow-up care.
Recovery & After-Care
- Minimal recovery required for blood tests and imaging
- Short rest may be needed if biopsy is performed
- Regular follow-up scheduled based on risk category
- Lifestyle and preventive measures may be recommended
Results & Interpretation
Cancer risk stratification provides:
- Classification into low, intermediate, or high-risk categories
- Identification of patients requiring immediate intervention
- Guidance for active surveillance or personalized treatment
- Data for long-term monitoring and follow-up
Accurate risk stratification helps optimize patient outcomes and reduce unnecessary procedures.
Why Korea Is a Top Destination
- Advanced diagnostic technology including PSA panels, PHI, 4Kscore, mpMRI, and genetic testing
- Experienced urologists specializing in prostate cancer risk assessment
- Fast, accurate, and internationally-friendly service
- Integration of imaging and biopsy for precise stratification
- English-language support and medical tourism coordination
- Cost-effective and high-quality care compared to Western countries
Cost Range
Typical costs for cancer risk stratification in Korea:
₩500,000 – ₩2,500,000 KRW (~$400–$2,000 USD)
Costs vary depending on:
- Number of tests performed (PSA, PHI, 4Kscore, imaging, biopsy)
- Hospital or clinic grade
- Consultation and follow-up services
Popular Clinics in Korea
- Seoul National University Hospital – Prostate Cancer Risk Stratification
- Samsung Medical Center – Advanced Urology & Risk Assessment
- Asan Medical Center – Comprehensive Prostate Cancer Evaluation
- Gangnam Severance Hospital – International Patient Risk Stratification Services
- Korea University Anam Hospital – Personalized Prostate Risk Assessment
- JK Urology & Men’s Health Clinics – Cancer Risk Stratification & Follow-Up
